Tim Alexander Ludwig

Tim Alexander Ludwig

Auto-generated profile, based on publicly available information

Tim Alexander Ludwig

Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Journal of Endourology
Verified
Journal Article
Closed access
PGPhilipp Gild
Philipp Gild
LLLukas Lenke
Lukas Lenke
RPRaisa Sinaida Pompe
Raisa Sinaida Pompe
MVMalte Wolfram Vetterlein
Malte Wolfram Vetterlein
TLTim Alexander Ludwig
Tim Alexander Ludwig
ABAndreas Becker
Andreas Becker
Purpose: To assess perioperative outcomes of HoLEP in a real-world scenario and with a focus on demanding patient factors such as large prostate size, advanced patient age, and anticoagulation therapy (AT). Material & Methods: We retrospectively analysed HoLEP procedures at our institution between 2010-2016. After stratification by prostate volume, age, and AT, perioperative and early voiding characteristics were compared. A multivariable regression model was employed to identify predictors of prolonged time of catheterization (defined as being above groups median). Results: The study cohort consisted of 1,816 men with a median age of 71 years (IQR:66-76), a median prostate volume of 80 ml (IQR:58-105) and American Society of Anesthesiologists (ASA) score ≥3 in 618 men (34%). Median time of enucleation and morcellation were 43 min (IQR:31-60) and 10 min (IQR:6-18), respectively. Perioperative blood transfusions were administered in 44 (2.4%) cases, severe postoperative complications (Clavien-Dindo grade ≥3b) occured in 61 (3.3%) of cases. The median time of catheterization was 2 days (IQR: 2-2), with prolonged catheterization occuring in 277 (15%) of cases. After adjustment, very large prostates (4th volume quartile (106-280ml) (OR:1.8, 95%CI:1.3-2.6, p=0.001), therapeutic low-molecular-weight heparin bridging regimen (OR: 2.2, 95%CI:1.4-3.6, p=0.037), low-dose acetylsalicyclic acid (OR:1.5, 95%CI:1.0-2.2, p=0.015), and a history of direct oral anticoagulation (OR:2.3, 95%CI:1.2-4.0, p=0.022), but not patient age, were independently associated with prolonged catherization. Conclusions: We confirm HoLEP as safe and efficient; however, patients with very large prostates and patients with a history of anticoagulation therapy are at risk of prolonged catheterization.

2 March 2026 in Die Urologie
Verified
Journal Article
Closed access
PDF file
NRNavid Roessler
Navid Roessler
RSRobert J. Schulz
Robert J. Schulz
MWMax C. Wagner
Max C. Wagner
MVMalte W. Vetterlein
Malte W. Vetterlein
RDRoland Dahlem
Roland Dahlem
TLTim A. Ludwig
Tim A. Ludwig

12 March 2015
Verified
Book Chapter
Closed access
PDF file
TLTim Alexander Ludwig
Tim Alexander Ludwig
RDRoland Dahlem
Roland Dahlem

1 February 2026 in Journal of Urology
Verified
Journal Article
Open access
MDMeghan F. Davis
Meghan F. Davis
DNDmitriy Nikolavsky
Dmitriy Nikolavsky
ACAndre G. Cavalcanti
Andre G. Cavalcanti
BFBrian of Colorado Flynn
Brian of Colorado Flynn
RGReynaldo Gomez
Reynaldo Gomez
KVKrishnan Venkatesan
Krishnan Venkatesan
The artificial urinary sphincter (AUS) is the gold standard for male stress urinary incontinence (SUI). There is limited and conflicting evidence examining outcomes in AUS insertion after urethroplasty particularly whether and how urethroplasty techniques affect them. We evaluated complications of AUS insertion after urethroplasty in a multi-institutional cohort. We hypothesize that complications occur at higher rates and vary between transecting and non-transecting urethroplasty. We retrospectively reviewed patients who underwent AUS after urethroplasty at 15 institutions. Demographic and clinical variables were analyzed. Urethroplasties were categorized as transecting or non-transecting. Long-term complications included AUS infection, erosion, and mechanical failure. 178 cases were identified performed by 17 surgeons (range 4-40) from 15 institutions with median follow-up of 33.5 (IQR 46) months). AUS complications requiring explantation, including infection, erosion and mechanical failure following transecting urethroplasty occurred in 56.2% compared to 23.5% following non-transecting urethroplasty (p < 0.001). Transecting urethroplasty technique was correlated with increased risk of device explant both from erosion (p=0.004) and atrophy (p=0.008). Radiation (HR 0.46, 95% CI 0.28-0.76, p=0.002), hypertension (HR 0.44, 95% CI 0.27-0.73, p=0.0008) and patient age (>68) (HR 0.5, 95% CI 0.3-0.81, p=0.004) also correlated to risk of device explantation. Risk of experiencing AUS complications is higher in patient with transecting urethroplasty compared to the non-transecting group. Non-transecting urethroplasty may be advisable if a subsequent need for AUS is anticipated.

1 February 2018 in Der Urologe
Verified
Journal Article
Closed access
PDF file
TLT. A. Ludwig
T. A. Ludwig
RDR. Dahlem
R. Dahlem